HealthDay Insights on Combo Therapy and Advanced Kidney Cancer Survival
HealthDay Insights on Innovative Drug Combinations for Kidney Cancer
A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer. Researchers at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., developed the new regimen, a combination of pazopanib (Votrient) and bevacizumab (Avastin).
The Mechanism of Action
Pazopanib is from a class of cancer drugs known as tyrosine kinase inhibitors (TKIs) that work by blocking vascular endothelial growth factor (VEGF) signaling, a vital mechanism for cancer cell growth. In trials leading to its FDA approval, pazopanib was found to achieve an average progression-free survival of over 11 months.
Clinical Trial Findings
The new trial involved 51 patients and discovered that combining pazopanib with bevacizumab doubled the average progression-free survival to more than 23 months. Patients received pazopanib in 10-week treatment cycles, initially on days 1 to 28.
- Dr. Saby George led the research team to investigate treatment efficacy.
- The strategy involved introducing bevacizumab midway through the treatment cycle (days 36 to 50).
This approach addresses the issue of VEGF upregulation, which can lead to cancer resistance against pazopanib.
For more information on groundbreaking cancer treatments, please visit the source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.